Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2002 Settembre;46(3) > The Quarterly Journal of Nuclear Medicine 2002 Settembre;46(3):171-80

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine 2002 Settembre;46(3):171-80

NOVEL METHODS OF ALTERING PHARMACOKINETICS IN RADIOPHARMACEUTICAL DESIGN
Guest Editor: Hnatowich D. 

Polyethylene glycol in the design of tumor-targetting radiolabelled macromolecules - lessons from liposomes and monoclonal antibodies

Harrington K. J. 1, Mubashar M. 2, Peters A. M. 2

1 Cancer Research UK Laboratory of Targetted Therapy Centre for Cell and Molecular Biology Institute of Cancer Research, London, UK
2 Department of Nuclear Medicine, Addenbrooke’s Hospital Cambridge, UK

Radiolabelled mac­ro­mol­e­cules ­such as lipo­somes and mono­clo­nal anti­bod­ies (Mab) are attrac­tive ­agents for ­tumour-tar­get­ting stud­ies. In addi­tion to ­their poten­tial diag­nos­tic ­role, ­they can ­also pro­vide ­vital infor­ma­tion on the tar­get­ting capac­ity of ther­a­peu­tic ­agents. Certainly in the ­case of lipo­some devel­op­ment, ­this abil­ity to ­track the phar­ma­cok­i­net­ics and bio­dis­trib­u­tion of the ­agents in a non-inva­sive fash­ion has assist­ed the ­design and appli­ca­tion of ther­a­peu­tic lip­o­so­mal ­agents. A sig­nif­i­cant lim­i­ta­tion of unmod­i­fied lipo­somes and Mab is ­their ten­den­cy to be ­cleared rap­id­ly ­from the cir­cu­la­tion. The use of poly­eth­y­lene gly­col (PEG) in the for­mu­la­tion of ­these ­agents has the capac­ity to ­alter ­their bio­log­i­cal beha­vi­our in ­such a way as to ­improve ­their abil­ity to tar­get ­tumours. In ­this ­paper we ­review the ­data relat­ing to the use of PEG-mod­i­fied lipo­somes and Mab in the con­text of nucle­ar med­i­cine stud­ies.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina